Tenderwize
Back to tender search

Open House Discount Agreements for Icatibant

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 222 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Icatibant, ATC B06AC02

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for Icatibant (ATC B06AC02) medicinal products.
  • Contracts valid from June 2025 to May 2027 with rolling monthly entry.
Show full summary

This is an Open House (non-exclusive) discount agreement procedure for the active ingredient Icatibant (ATC B06AC02) organized by AOK Rheinland-Pfalz/Saarland. It is not a public procurement under EU Directive 2014/24 but published for transparency. All pharmaceutical companies can join under uniform terms from June 2025 to May 2027, with monthly entry possible. Estimated value is not provided. Only one lot exists. No procurement documents were analyzed, only the notice itself.

Risks

No estimated value or minimum purchase commitment; revenue uncertainty. Buyer may replace open-house with exclusive con...

Strict proof of marketability required; incomplete documentation may delay or prevent participation.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) with authorized and marketable medicines in Germany.
  • Medicines must be listed in Lauer-Taxe as marketable or provide proof via AMIce database extracts.
  • Children's medicines (according to BfArM list) are excluded.

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified; open-house model with uniform terms for all participants.

Buyer

Lots (1)

LOT-0001

Open House Discount Agreements for Icatibant

Non-exclusive discount agreements for pharmaceutical products containing Icatibant (ATC B06AC02). Contracts last maximum 24 months, ending no later than 31.05.2027. Entry possible on the first of each month. The buyer may replace open-house contracts with exclusive contracts from competitive procedures. Children's medicines according to BfArM list are excluded.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified; open-house model with uniform terms for all participants.

Deadline

Deadline Mar 31, 2027

Procurement Details

Publication date
10 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
235827-2025

Documents (1)

Similar tenders